NEW YORK (GenomeWeb News) - Ipsogen said today it has granted Warnex exclusive rights to market its JAK2 leukemia diagnostic test in Canada.
The test is based on variations in the JAK2 gene, for which Ipsogen holds intellectual property rights. It detects certain mutations in the gene linked to myeloproliferative disorders, including myelogenous leukemia, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis.
Ipsogen said it offers the test as both a product and via a licensing program.
Financial terms of the agreement were not released.